Adelaide Research & Scholarship
Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/9567
| Citations | ||
| Scopus | Web of Science® | Altmetric |
|---|---|---|
|
?
|
?
|
|
| Type: | Journal article |
| Title: | The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE) |
| Author: | Pan, B. Farrugia, A. To, L. Findlay, D. Green, J. Lynch, K. Zannettino, A. |
| Citation: | Journal of Bone and Mineral Research, 2004; 19(1):147-154 |
| Publisher: | Amer Soc Bone & Mineral Res |
| Issue Date: | 2004 |
| ISSN: | 0884-0431 1523-4681 |
| Statement of Responsibility: | Beiqing Pan, Amanda N Farrugia, Luen Bik To, David M Findlay, Jonathan Green, Kevin Lynch, Andrew CW Zannettino |
| Abstract: | Bisphosphonates are used to prevent osteoclast-mediated bone loss. Zoledronic acid inhibits osteoclast maturation indirectly by increasing OPG protein secretion and decreasing transmembrane RANKL expression in human osteoblasts. The decreased transmembrane RANKL expression seems to be related to the upregulation of the RANKL sheddase, TACE. |
| Keywords: | Cells, Cultured Osteoblasts Humans Hydroxamic Acids Diphosphonates Imidazoles Metalloendopeptidases Carrier Proteins Membrane Glycoproteins Receptors, Tumor Necrosis Factor Blotting, Western Flow Cytometry Immunohistochemistry Gene Expression ADAM Proteins RANK Ligand Receptor Activator of Nuclear Factor-kappa B Osteoprotegerin ADAM17 Protein Zoledronic Acid |
| Description: | © American Society for Bone and Mineral Research. |
| DOI: | 10.1359/jbmr.2004.19.1.147 |
| Published version: | http://dx.doi.org/10.1359/jbmr.2004.19.1.147 |
| Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.